- Client:Leuko
- Sector: Medical, Health
- Services: Conceptualization, Conceptualization, Industrialization
- Year: 2022
- Team:
Design Lead, Ramon Martínez
Dissenyador Senior de Producte, Ruben Belde
The first noninvasive device for the screening of severe neutropenia
In chemotherapy treatments it is crucial to monitor the levels of white blood cells of the patient.
Knowing in real time if this side effect of treatment is occurring can significantly reduce the 250,000+ infections and hospital readmissions that happen annually in Europe for these patients. Leuko’s research team has developed a noninvasive and portable home device able to detect the levels of white blood cells in a patient, making it not necessary to have a blood sample.
Need
Transform a complex process into a simple, easy and clean seamless human experience
Leuko’s technology is being proved and tested with chemotherapy patients to ensure usability and diagnostic performance. This process was demanding in terms of precision and simplicity, so new smart solutions were needed in order to elevate the patient’s experience.
Process
Design exploration, human factors and rapid prototyping
This is the formula that the design team came up with to conceive a user-friendly, non-invasive domestic device.
Delivering a user-friendly, intuitive and hassle free device is key for the success of Leuko’s Value Proposition. Without the engagement and convenience of an excellent UX, the adhesion of the audience is at risk, and so it is the entire system. Both hardware and software design solutions where provided by Stimulo, including an easy-to-clean, smooth and oil-spills-proof finger Cartridge, a compact cutting-edge domestic device able to minimize the patient stigma, and an intuitive digital interaction especially designed for the elderly.
Value
Empowered patients
Portable and designed for home use, the finger-based test takes one minute to non-invasively capture enough information to assess white blood cell levels, improving the quality of life for many patients who will be able to do the test at home in a non-invasive way (without the need of withdrawing blood), which means a significant saving in healthcare costs.
Knowhow
It’s a research device. It’s not for sale
Today, the PointCheck™ device is being tested by the FDA and CE Mark, the previous step to revolutionise the way millions of immunosuppressed patients can be tested and treated, moving towards improved quality of life and improved clinical outcomes.
